Digital Twins, Agents & Clinical AI Workflows
Key Questions
What research highlights reliability issues with AI agents in clinical settings?
ICML 2026 papers, the Meta-Agent Challenge on reward hacking, and Stanford studies show two-agent degradation and token cost explosions. AutoMedBench further reveals verification failures in agent workflows.
How are digital twins being explored for personalized medicine?
Panels discuss practical issues of regulation, bias, and physician adoption when every patient has a digital twin, with medical imaging as the dominant data source in current implementations.
What deployments of purpose-built AI agents are occurring in pharma?
Owkin-Sanofi and Novo Nordisk have deployed agents, with Q&A sessions emphasizing purpose-built designs over general models. New frameworks like MLEvolve and EvoDS support these enterprise workflows.
Why do hospitals struggle to measure real-world AI impact?
Only 15% of deployed AI reaches clinical use despite 70% deployment rates, compounded by a 77% clinician trust gap and shifting EU AI Act timelines to 2028.
What benchmarks and new agent frameworks are emerging for scientific discovery?
Agents' Last Exam, MIA evaluations across 15 cancer types, and Sakana AI's RSI Lab for recursive improvement are advancing the field alongside calls for specialist agent crews.
Agent reliability research gaining traction: ICML 2026 paper, Meta-Agent Challenge (reward hacking), Stanford two-agent degradation study, token cost explosion. New agent frameworks (MLEvolve, EvoDS, MemTrain, StreamMA). Owkin-Sanofi and Novo Nordisk deployments. AutoMedBench highlights verification failures. Cost-effectiveness study supports human-AI copilot. Agents' Last Exam benchmark. Sakana AI RSI Lab for recursive self-improvement. Adaptive Innovations raises $60M for AI-native home health provider. Why Hospitals Cannot Measure AI Impact – 70% deployment vs 15% clinical use, 77% clinician trust gap, EU AI Act timeline shift to 2028. Surgical Robots Already Clocking Hospital Shifts – high-level snapshot of physical AI deployment. AI moves into pharma's core operations (pharmacovigilance, quality control) – enterprise-wide adoption and governance challenges. Agent #25 – scientific discovery agent mapping negative space. MIA evaluation of AI agents for biological discovery (Broad Institute) – benchmarking across 15 cancer types, copilot vs autonomous. New: Stanford symposium overview includes agentic workflows. New: BMS CEO fireside chat on real-world AI impact. New: Caris Life Sciences CMO discussion. New: Strategic CIO perspective on building AI-ready health organizations. New: LabVLA grounds VLA models in scientific labs – step toward autonomous experimentation. New: Article argues for specialist agent crews over monolithic models. New: Owkin-Sanofi Q&A adds depth on purpose-built AI agents. New: Kedar Mate on Qualified Health AI – practical insights for safe scaling. New: Healthcare AI deployment requires clear roles and honest communication. New: DLD Health panel with Roche, Siemens, OpenAI on AI in life sciences. New: Digital twin panel (What If Every Patient Had a Digital Twin? Part 2) offers practical perspectives on regulation, bias, and physician adoption.